Amgen’s Q1 Overshadowed By Tax Dispute That May Cost $7.1bn To Resolve
IRS Identifies $5.1bn Shortfall, Proposes $2bn Penalty
First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang.
